Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Bath BA2 7AY, United Kingdom
Department of Chemistry, University of Bath, Bath BA2 7AY, United Kingdom
Faculty of Medicine, Imperial College London, St. Mary's Hospital, London W2 INY, United Kingdom
IPSEN System Biology, 91966 Les Ulis, France
Istituto di Biostrutture e Bioimmagini-CNR, Naples, Italy
Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Florence, Italy
References: Folkman, J., Bach, M., Rowe, J.W., Davidoff, F., Lambert, P., Hirsch, C., Goldberg, A., Henshaw, E., Tumor angiogenesis: Therapeutic implications (1971) New Engl. J. Med, 285, pp. 1182-118
Ferrara, N., Kerbel, R.S., Angiogenesis as a therapeutic target (2005) Nature, 438, pp. 967-974
Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) Nat. Rev. Drug Discovery, 3, pp. 391-400
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer (2004) New Engl. J. Med, 350, pp. 2335-2342
Jain, R.K., Duda, D.G., Clark, J.W., Loeffler, J.S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006) Nat Clin. Pract. Oncol, 3, pp. 24-40
Leese, M.P., Hejaz, H.A.M., Mahon, M.F., Newman, S.P., Purohit, A., Reed, M., Potter, B.V.L., A-ring substituted estrogen sulfamates: Potent multi-targeted anti-cancer agents (2005) J. Med. Chem, 48, pp. 5243-5256
Leese, M.P., Newman, S.P., Purohit, A., Reed, M.J., Potter, B.V.L., 2-Alkylsulfanyl estrogen derivatives: Synthesis of a novel class of multi-targeted anti-tumor agents (2004) Bioorg. Med. Chem. Lett, 14, pp. 3135-3138
Leese, M.P., Leblond, B., Newman, S.P., Purohit, A., Reed, M.J., Potter, B.V.L., Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates (2005) J. Steroid Biochem. Mol. Biol, 94, pp. 239-251
Purohit, A., Hejaz, H.A.M., Walden, L., MacCarthy-Morrogh, L., Packham, G., Potter, B.V.L., Reed, M.J., The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours (2000) Int. J. Cancer, 85, pp. 584-589
Newman, S.P., Leese, M.P., Purohit, A., James, D.R.C., Rennie, C.E., Potter, B.V.L., Reed, M.J., Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates (2004) Int. J. Cancer, 109, pp. 533-540
Chander, S.K., Foster, P.A., Leese, M.P., Newman, S.P., Potter, B.V.L., Purohit, A., Reed, M.J., In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol (2007) Br. J. Cancer, 96, pp. 1368-1376
Wood, L., Leese, M.P., Mouzakiti, A., Purohit, A., Potter, B.V.L., Reed, M.J., Packham, G., 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases (2004) Apoptosis, 9, pp. 323-332
Newman, S.P., Ireson, C.R., Tutill, H.J., Day, J.M., Parsons, M.F.C., Leese, M.P., Potter, B.V.L., Purohit, A., The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer (2006) Cancer Res, 66, pp. 324-330
Ireson, C.R., Chander, S.K., Purohit, A., Perera, S., Newman, S.P., Parish, D., Leese, M.P., Reed, M.J., Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents (2004) Br. J. Cancer, 90, pp. 932-937
Reed, M.J., Purohit, A., Newman, S.P., Potter, B.V.L., Steroid sulfatase: Molecular biology, regulation and inhibition (2005) Endocr. Rev, 26, pp. 171-202
Ho, Y.T., Purohit, A., Vicker, N., Newman, S.P., Robinson, J.J., Leese, M.P., Ganeshapillai, D., Reed, M.J., Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates (2003) Biochem. Biophys. Res. Commun, 305, pp. 909-914
Stanway, S.J., Purohit, A., Woo, L.W.L., Sufi, S., Vigushin, D., Ward, R., Wilson, R., Coombs, R.C., Phase I study of STX64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor (2006) Clin. Cancer Res, 12, pp. 1585-1592
Stanway, S.J., Delavault, P., Purohit, A., Woo, L.W.L., Thurieau, C., Potter, B.V.L., Reed, M.J., Steroid sulfatase: A new target for the endocrine therapy of breast cancer (2007) Oncologist, 12, pp. 370-374
Hussain, S.A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., Murray, P.G., Palmer, D.H., Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer (2007) Br. J. Cancer, 96, pp. 104-109
Cushman, M., He, H.M., Katzenellenbogen, J.A., Varma, R.K., Hamel, E., Lin, C.M., Ram, S., Sachdeva, Y.P., Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth (1997) J. Med. Chem, 40, pp. 2323-2334
Klauber, N., Parangi, S., Flynn, E., Hamel, E., D'Amato, R.J., Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol (1997) Cancer Res, 57, pp. 81-86
Abbate, F., Winum, J.Y., Potter, B.V.L., Casini, A., Montera, J.L., Scozzafava, A., Supuran, C.T., Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase (2004) Bioorg. Med. Chem. Lett, 14, pp. 231-234
Elger, W., Schwarz, S., Hedden, A.M., Reddersen, G., Schneider, B., Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application (1995) J. Steroid Biochem. Mol. Biol, 55, pp. 395-403
Dahut, W.L., Lakhani, N.J., Gulley, J.L., Arlen, P.M., Kohn, E.C., Kotz, H., McNally, D., Figg, W.D., Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors (2006) Cancer Biol. Ther, 5, pp. 22-27
Sutherland, T.E., Anderson, R.L., Hughes, R.A., Altmann, E., Schuliga, M., Ziogas, J., Stewart, A.G., 2-Methoxyestradiol: A unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents (2007) Drug Discovery Today, 12, pp. 577-584
Potter, B. V. L. 3,17-Disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anti-cancer activity. J. Med. Chem. 2007, 50, 4443Okada, M., Iwashita, S., Koizumi, N., Efficient general method for sulfamoylation of a hydroxyl group (2000) Tetrahedron Lett, 41, pp. 7047-7051
Burgess, E.M., Penton, H.R., Taylor, E.A., Synthetic applications of N-carboalkoxysulfamate esters (1970) J. Am. Chem. Soc, 92, pp. 5224-5226
Ohira, S., Methanolysis of dimethyl(1-diazo-2-oxopropyl)phosphonate. Generation of (diazomethyl) phosphonate and reaction with carbonyl compounds (1989) Synth. Commun, 19, pp. 561-564
Tinley, T.L., Leal, R.M., Randall-Hlubek, D.A., Cessac, J.W., Wilkens, L.R., Rao, P.N., Mooberry, S.L., Novel 2-methoxyestradiol analogues with antitumor activity (2003) Cancer Res, 63, pp. 1538-1549
Boyd, M.R., Pauli, K.D., Some practical consideration and applications of the National Cancer Institute in vitro anticancer drug discovery screen (1995) Drug Dev. Res, 34, pp. 91-109
Shoemaker, R.H., The NCI 60 human tumor cell line screen: An information-rich screen informing on mechanisms of toxicity (2006) In Vitro Cell. Dev. Biol.: Anim, 42, pp. 5A
Newman, S.P., Foster, P.A., Ho, Y.T., Day, J.M., Raobaikady, B., Kasprzyk, P.G., Leese, M.P., Purohit, A., The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disrupters as therapy for hormone-independent prostate and breast cancers (2007) Br. J. Cancer, 97, pp. 1673-1682
Purohit, A., Williams, G.J., Howarth, N.M., Potter, B.V.L., Reed, M.J., Inactivation of steroid sulfatase by an active site directed inhibitor, estrone-3-O-sulfamate (1995) Biochemistry, 34, pp. 11508-11514
Lloyd, M.D., Thiyagarajan, N., Ho, Y.T., Woo, L.W.L., Sutcliffe, O.B., Purohit, A., Reed, M.J., Potter, B.V.L., First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors (2005) Biochemistry, 44, pp. 6858-6866
Appel, R., Berger, G., Uber das hydrazidosulfamid (On hydrazidosulfamide) (1958) Chem. Ber, 91, pp. 1339-1341
Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5(10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J. Steroid Biochem. Mol. Biol. 1996, 57, 79-88Otwinowski, Z., Minor, W., Processing of X-ray diffraction data collected in oscillation mode (1997) Method Enzymol, 276, pp. 307-326
Eriksson, A.E., Jones, T.A., Liljas, A., Refined structure of human carbonic anhydrase II at 2.0Å resolution (1988) Proteins, 4, pp. 274-282
Brunger, A.T., Adams, P.D., Clore, G.M., Delano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Warren, G.L., Crystallography & NMR system: A new software suite for macromolecular structure determination (1998) Acta Crystallogr., Sect. D, 54, pp. 905-921
Jones, T.A., Zou, J.Y., Cowan, S.W., Kjeldgaard, M., Improved methods for building protein models in electron-density maps and the location of errors in these models (1991) Acta Crystallogr., Sect. A, 47, pp. 110-119
Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr, 26, pp. 283-291
Jain, R. K., Duda, D. G., Clark, J. W., Loeffler, J. S., Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006) Nat Clin. Pract. Oncol, 3, pp. 24-40
Leese, M. P., Hejaz, H. A. M., Mahon, M. F., Newman, S. P., Purohit, A., Reed, M., Potter, B. V. L., A-ring substituted estrogen sulfamates: Potent multi-targeted anti-cancer agents (2005) J. Med. Chem, 48, pp. 5243-5256
Leese, M. P., Newman, S. P., Purohit, A., Reed, M. J., Potter, B. V. L., 2-Alkylsulfanyl estrogen derivatives: Synthesis of a novel class of multi-targeted anti-tumor agents (2004) Bioorg. Med. Chem. Lett, 14, pp. 3135-3138
Leese, M. P., Leblond, B., Newman, S. P., Purohit, A., Reed, M. J., Potter, B. V. L., Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates (2005) J. Steroid Biochem. Mol. Biol, 94, pp. 239-251
Newman, S. P., Leese, M. P., Purohit, A., James, D. R. C., Rennie, C. E., Potter, B. V. L., Reed, M. J., Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates (2004) Int. J. Cancer, 109, pp. 533-540
Chander, S. K., Foster, P. A., Leese, M. P., Newman, S. P., Potter, B. V. L., Purohit, A., Reed, M. J., In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol (2007) Br. J. Cancer, 96, pp. 1368-1376
Newman, S. P., Ireson, C. R., Tutill, H. J., Day, J. M., Parsons, M. F. C., Leese, M. P., Potter, B. V. L., Purohit, A., The role of 17 -hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer (2006) Cancer Res, 66, pp. 324-330
Ireson, C. R., Chander, S. K., Purohit, A., Perera, S., Newman, S. P., Parish, D., Leese, M. P., Reed, M. J., Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol- bis-sulphamate in vivo in rodents (2004) Br. J. Cancer, 90, pp. 932-937
Reed, M. J., Purohit, A., Newman, S. P., Potter, B. V. L., Steroid sulfatase: Molecular biology, regulation and inhibition (2005) Endocr. Rev, 26, pp. 171-202
Ho, Y. T., Purohit, A., Vicker, N., Newman, S. P., Robinson, J. J., Leese, M. P., Ganeshapillai, D., Reed, M. J., Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates (2003) Biochem. Biophys. Res. Commun, 305, pp. 909-914
Stanway, S. J., Purohit, A., Woo, L. W. L., Sufi, S., Vigushin, D., Ward, R., Wilson, R., Coombs, R. C., Phase I study of STX64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor (2006) Clin. Cancer Res, 12, pp. 1585-1592
Stanway, S. J., Delavault, P., Purohit, A., Woo, L. W. L., Thurieau, C., Potter, B. V. L., Reed, M. J., Steroid sulfatase: A new target for the endocrine therapy of breast cancer (2007) Oncologist, 12, pp. 370-374
Hussain, S. A., Ganesan, R., Reynolds, G., Gross, L., Stevens, A., Pastorek, J., Murray, P. G., Palmer, D. H., Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer (2007) Br. J. Cancer, 96, pp. 104-109
Dahut, W. L., Lakhani, N. J., Gulley, J. L., Arlen, P. M., Kohn, E. C., Kotz, H., McNally, D., Figg, W. D., Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors (2006) Cancer Biol. Ther, 5, pp. 22-27
Sutherland, T. E., Anderson, R. L., Hughes, R. A., Altmann, E., Schuliga, M., Ziogas, J., Stewart, A. G., 2-Methoxyestradiol: A unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents (2007) Drug Discovery Today, 12, pp. 577-584
Burgess, E. M., Penton, H. R., Taylor, E. A., Synthetic applications of N-carboalkoxysulfamate esters (1970) J. Am. Chem. Soc, 92, pp. 5224-5226
Tinley, T. L., Leal, R. M., Randall-Hlubek, D. A., Cessac, J. W., Wilkens, L. R., Rao, P. N., Mooberry, S. L., Novel 2-methoxyestradiol analogues with antitumor activity (2003) Cancer Res, 63, pp. 1538-1549
Boyd, M. R., Pauli, K. D., Some practical consideration and applications of the National Cancer Institute in vitro anticancer drug discovery screen (1995) Drug Dev. Res, 34, pp. 91-109
Shoemaker, R. H., The NCI 60 human tumor cell line screen: An information-rich screen informing on mechanisms of toxicity (2006) In Vitro Cell. Dev. Biol.: Anim, 42, pp. 5A
Newman, S. P., Foster, P. A., Ho, Y. T., Day, J. M., Raobaikady, B., Kasprzyk, P. G., Leese, M. P., Purohit, A., The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disrupters as therapy for hormone-independent prostate and breast cancers (2007) Br. J. Cancer, 97, pp. 1673-1682
Lloyd, M. D., Thiyagarajan, N., Ho, Y. T., Woo, L. W. L., Sutcliffe, O. B., Purohit, A., Reed, M. J., Potter, B. V. L., First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors (2005) Biochemistry, 44, pp. 6858-6866
Eriksson, A. E., Jones, T. A., Liljas, A., Refined structure of human carbonic anhydrase II at 2. 0 resolution (1988) Proteins, 4, pp. 274-282
Brunger, A. T., Adams, P. D., Clore, G. M., Delano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Warren, G. L., Crystallography & NMR system: A new software suite for macromolecular structure determination (1998) Acta Crystallogr., Sect. D, 54, pp. 905-921
Jones, T. A., Zou, J. Y., Cowan, S. W., Kjeldgaard, M., Improved methods for building protein models in electron-density maps and the location of errors in these models (1991) Acta Crystallogr., Sect. A, 47, pp. 110-119
Laskowski, R. A., MacArthur, M. W., Moss, D. S., Thornton, J. M., PROCHECK: A program to check the stereochemical quality of protein structures (1993) J. Appl. Crystallogr, 26, pp. 283-291
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(289 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote